CD56 is Expressed in Uterine Smooth Muscle Tumors

Karpathiou, Georgia; Chauleur, Céline; Papoudou‐Bai, Alexandra; Dagher, Sami; Péoc’h, Michel

doi:10.1097/pgp.0000000000000696

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And all adjacent slices were stained with hematoxylin and eosin (H&E) based on the basic protocol. The percentage of positive stained was conculcated as follows ( Karpathiou et al, 2021 ): 0 = 0%, 1 = 0–25%, 2 = 26–50%, 3 = 51–75%, 4 = 76–100%. The intensity scoring was conducted as follows: 0 = no staining, 1 = weak, 2 = moderate, 3 = strong.…”

Section: Methodsmentioning

confidence: 99%

PLP1 may serve as a potential diagnostic biomarker of uterine fibroids

Cai

Liao²,

Li³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Objective: We aim to identify the crucial genes or potential biomarkers associated with uterine fibroids (UFs), which may provide clinicians with evidence about the diagnostic biomarker of UFs and reveal the mechanism of its progression.Methods: The gene expression and genome-wide DNA methylation profiles were obtained from Gene Expression Omnibus database (GEO). GSE45189, GSE31699, and GSE593 datasets were included. GEO2R and Venn diagrams were used to analyze the differentially expressed genes (DEGs) and extract the hub genes. Gene Ontology (GO) analysis was performed by the online tool Database for Annotation, Visualization, and Integrated Discovery (DAVID). The mRNA and protein expression of hub genes were validated by RT-qPCR, western blot, and immunohistochemistry. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value.Results: We detected 22 DEGs between UFs and normal myometrium, which were enriched in cell maturation, apoptotic process, hypoxia, protein binding, and cytoplasm for cell composition. By finding the intersection of the data between differentially expressed mRNA and DNA methylation profiles, 3 hub genes were identified, including transmembrane 4 L six family member 1 (TM4SF1), TNF superfamily member 10 (TNFSF10), and proteolipid protein 1 (PLP1). PLP1 was validated to be up-regulated significantly in UFs both at mRNA and protein levels. The area under the ROC curve (AUC) of PLP1 was 0.956, with a sensitivity of 79.2% and a specificity of 100%. Conclusion: Overall, our results indicate that PLP1 may be a potential diagnostic biomarker for uterine fibroids.

show abstract

Section: Methodsmentioning

confidence: 99%

PLP1 may serve as a potential diagnostic biomarker of uterine fibroids

Cai

Liao²,

Li³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…The percentage of stained samples that were positive was calculated as 0 = negative, 1 = < 10%, 2 = 10%-49%, and 3 = ≥ 50%. According to the intensity scale, 0 indicates no Frontiers in Genetics frontiersin.org staining, 1 is little, 2 is moderate, and 3 is strong (Karpathiou et al, 2021). The percentage and intensity were multiplied to determine the final results for each section.…”

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

Subtypes analysis and prognostic model construction based on lysosome-related genes in colon adenocarcinoma

Yang

Huang

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Lysosomes are essential for the development and recurrence of cancer. The relationship between a single lysosome-related gene and cancer has previously been studied, but the relationship between the lysosome-related genes (LRGs) and colon adenocarcinoma (COAD) remains unknown. This research examined the role of lysosome-related genes in colon adenocarcinoma.Methods: 28 lysosome-related genes associated with prognosis (PLRGs) were found by fusing the gene set that is differently expressed between tumor and non-tumor in colon adenocarcinoma with the gene set that is related to lysosomes. Using consensus unsupervised clustering of PLRGs, the colon adenocarcinoma cohort was divided into two subtypes. Prognostic and tumor microenvironment (TME) comparisons between the two subtypes were then made. The PLRGs_score was constructed using the least absolute shrinkage and selection operator regression (LASSO) method to quantify each patient’s prognosis and provide advice for treatment. Lastly, Western Blot and immunohistochemistry (IHC) were used to identify MOGS expression at the protein level in colon adenocarcinoma tissues.Results: PLRGs had more somatic mutations and changes in genetic level, and the outcomes of the two subtypes differed significantly in terms of prognosis, tumor microenvironment, and enrichment pathways. Then, PLRGs_score was established based on two clusters of differential genes in the cancer genome atlas (TCGA) database, and external verification was performed using the gene expression omnibus (GEO) database. Then, we developed a highly accurate nomogram to enhance the clinical applicability of the PLRGs_score. Finally, a higher PLRGs_score was associated with a poorer overall survival (OS), a lower tumor mutation burden (TMB), a lower cancer stem cell (CSC) index, more microsatellite stability (MSS), and a higher clinical stage. MOGS was substantially elevated at the protein level in colon adenocarcinoma as additional confirmation.Conclusion: Overall, based on PLRGs, we identified two subtypes that varied significantly in terms of prognosis and tumor microenvironment. Then, in order to forecast patient prognosis and make treatment suggestions, we developed a diagnostic model with major significance for prognosis, clinical relevance, and immunotherapy. Moreover, we were the first to demonstrate that MOGS is highly expressed in colon adenocarcinoma.

show abstract

“…On a similar note, following the identification of SYP as a presynaptic vesicle protein in various neuronal tissues [ 4 ], succeeding studies identified SYP expression in pheochromocytoma and paraganglioma as well as in pancreatic islet cells and NETs [ 5 ]. CD56 (a cell adhesion molecule) and NSE (a glycolytic enzyme) have also been found expressed in various NETs, but the specificity is suboptimal as expression has been reported in unrelated tumors [ 6 , 7 , 8 , 9 , 10 ]. Apart from these markers of neuroendocrine differentiation, immunohistochemistry detecting expression of various hormones related to specific NET types is helpful, such as serotonin in small intestinal and appendiceal NETs and calcitonin in medullary thyroid carcinoma [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation

Juhlin

2021

Biology

View full text Add to dashboard Cite

When analyzing tumors by histopathology, endocrine pathologists have traditionally been restricted to a few key immunohistochemical markers related to secretory vesicles in order to pinpoint neuroendocrine differentiation—most notably Chromogranin A (CGA) and Synaptophysin (SYP). Although proven of great clinical utility, these markers sometimes exhibit tissue-specific patterns depending on tumor origin, and non-neuroendocrine tumors might sometimes display focal expression. Moreover, CGA and SYP might be partially or totally absent in highly proliferative neuroendocrine carcinomas, making the diagnosis particularly challenging on small biopsies of metastatic lesions with unknown location of the primary tumor. The advent of second-generation neuroendocrine markers ISL LIM Homeobox 1 (ISL1), INSM Transcriptional Repressor 1 (INSM1) and Secretagogin (SECG) have expanded the pathology toolbox considerably, constituting markers that often retain expression even in poorly differentiated neuroendocrine carcinomas. As non-neuroendocrine tumors seldom express these antigens, the specificity of ISL1, INSM1 and SECG make them welcome additions to clinical practice. In this commentary, recent advances of this field as well as initial clinical experiences from a tertiary neuroendocrine center are discussed.

show abstract

CD56 is Expressed in Uterine Smooth Muscle Tumors

Cited by 6 publications

References 14 publications

PLP1 may serve as a potential diagnostic biomarker of uterine fibroids

PLP1 may serve as a potential diagnostic biomarker of uterine fibroids

Subtypes analysis and prognostic model construction based on lysosome-related genes in colon adenocarcinoma

Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation

Contact Info

Product

Resources

About